

VVT MED INC.
(FORMERLY KNOWN AS DXI CAPITAL CORP.)

CONDENSED INTERIM
CONSOLIDATED FINANCIAL STATEMENTS
AS AT AND FOR THE THREE AND SIX MONTHS
ENDED JUNE 30, 2025

(UNAUDITED)

VVT MED INC.
(formerly known as DXI Capital Corp.)

TABLE OF CONTENTS

	<u>Page</u>
Notice to Shareholders	1
Unaudited Condensed Interim Consolidated Statements of Financial Position	2
Unaudited Condensed Interim Consolidated Statements of Loss	3
Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Deficit	4
Unaudited Condensed Interim Consolidated Statements of Cash Flows	5
Notes to the Unaudited Condensed Interim Consolidated Financial Statements	6

VVT MED INC.
(formerly known as DXI Capital Corp.)

NOTICE TO SHAREHOLDERS

The accompanying unaudited condensed interim consolidated financial statements of VVT MED INC. (formerly known as DXI Capital Corp.) as at and for the three and six months ended June 30, 2025, have been prepared by management in accordance with International Financial Reporting Standards applicable to interim financial statements (Note 2). Recognizing that the Company is responsible for both the integrity and objectivity of the unaudited condensed interim financial statements, management is satisfied that these unaudited condensed interim consolidated financial statements have been fairly presented.

Under National Instrument 51-102, part 4, sub-section 4.3 (3) (a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The Company's independent auditor has not performed a review of these unaudited condensed interim consolidated financial statements in accordance with standards established by the Institute of Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

VVT MED INC.
(formerly known as DXI Capital Corp.)
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Canadian dollars in thousands)

	<u>Note</u>	<u>June 30, 2025</u>	<u>December 31, 2024</u>
CURRENT ASSETS:			
Cash and cash equivalents		16	24
Prepaid and other receivables		6	3
Total current assets		22	27
TOTAL ASSETS		22	27
CURRENT LIABILITIES:			
Accounts payable and accrued liabilities		422	342
Loans from related parties	4	830	800
Total current liabilities		1,252	1,142
TOTAL LIABILITIES		1,252	1,142
SHAREHOLDERS' DEFICIT:			
Share capital	5	113,916	113,916
Contributed surplus		12,191	12,191
Retained deficit		(127,335)	(127,222)
Total shareholders' deficit		(1,228)	(1,115)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT		22	27

August 29, 2025	<i>"Yair Aloni"</i>	<i>"Erez Tetro"</i>
Date of the approval of the financial statements	Yair Aloni Chairman of the Board of Directors	Erez Tetro Chief Executive Officer and Director

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

VVT MED INC.
(formerly known as DXI Capital Corp.)
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS
(Canadian dollars in thousands, except for share and per share amounts)

	<u>Note</u>	<u>Three months ended June 30</u>		<u>Six months ended June 30</u>	
		<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
General and administrative expenses		59	21	81	43
Operating loss		(59)	(21)	(81)	(43)
Financing expenses	7	16	16	32	30
Net loss		(75)	(37)	(113)	(73)
Basic and diluted loss per share attributable to shareholders:		(0.006)	(0.003)	(0.009)	(0.006)
Weighted average number of common shares outstanding:		11,966,024	11,966,024	11,966,024	11,966,024

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

VVT MED INC.
(formerly known as DXI Capital Corp.)
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(Canadian dollars in thousands)

	<u>Share capital</u>	<u>Contributed surplus</u>	<u>Deficit</u>	<u>Total</u>
Balance as at January 1, 2025	113,916	12,191	(127,222)	(1,115)
Net loss	-	-	(113)	(113)
Balance as at June 30, 2025	113,916	12,191	(127,335)	(1,228)

	<u>Share capital</u>	<u>Contributed surplus</u>	<u>Deficit</u>	<u>Total</u>
Balance as at January 1, 2024	113,916	12,191	(127,064)	(957)
Net loss	-	-	(73)	(73)
Balance as at June 30, 2024	113,916	12,191	(127,137)	(1,030)

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

VVT MED INC.
(formerly known as DXI Capital Corp.)
NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS
(Canadian dollars in thousands)

	Six months ended June 30,	
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss for the period	(113)	(73)
Adjustments to reconcile net profit to net cash provided by operating activities:		
Increase in prepaids and deposits	(5)	2
Increase in accounts payable and accrued liabilities	80	12
Net cash used in operating activities	(38)	(59)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of plant and equipment	-	-
Net cash used in investment activities	-	-
CASH FLOWS FROM FINANCING ACTIVITIES:		
Advance of loans from related parties	30	60
Net cash provided by financing activities	30	60
Increase (decrease) in cash and cash equivalents	(8)	1
Cash and cash equivalents at beginning of the period	24	24
Cash and cash equivalents at the end of the period	16	25

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

VVT MED INC.
(formerly known as DXI Capital Corp.)
NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS
(Canadian dollars in thousands)

NOTE 1 – GENERAL

- A. VVT MED INC. (formerly known as DXI Capital Corp.) (the "**Company**" or "**VVT Med Inc.**") is a public company trading on the NEX under the symbol of "DXI.H", operated by the TSX Venture Exchange ("**TSXV**" or the "**Exchange**") in Canada, as of June 30, 2025.
- B. On September 11, 2021, the Company changed its name from DXI Energy Inc. to DXI Capital Corp. and effected a one hundred-to-one share consolidation of its common shares. All shares and per share amounts in these consolidated financial statements have been adjusted retroactively for all periods presented to reflect the effects of the share consolidation.
- C. The address of its registered office is 404 – 999 Canada Place, Vancouver, British Columbia.
- D. The Company has been engaged in the business of exploring and developing oil and gas assets in North America. In the first nine months of 2020, the Company disposed all its oil and gas assets. As of June 30, 2025, the Company has no active operations. The management and board of directors are currently forging a new direction for the Company's shareholders.
- E. These unaudited condensed interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, 0855524 B.C. Ltd., incorporated in British Columbia. These unaudited condensed interim consolidated financial statements also include the accounts of Dejour Energy (Alberta) Ltd. ("**DEAL**"), incorporated in Alberta, until May 31, 2020 and Dejour Energy (USA) Corp. ("**DUSA**"), incorporated in Nevada, until August 26, 2020. The Company sold its equity interest in DEAL entirely and deconsolidated these accounts from its financial statements on May 31, 2020, the effective date of the change of control. The 100% equity interest of DUSA was seized by one of the Company's secured lenders and these accounts were deconsolidated from its financial statements on August 26, 2020, the effective date of the change of control. All intercompany transactions are eliminated upon consolidation.
- F. On October 1, 2024, the Company entered into a definitive agreement dated September 30, 2024 (the "**Definitive Agreement**") with V.V.T. MED LTD ("**VVT**"), an Israeli-based private company manufacturing and developing medical products and Exiteam Acquisition Corp. ("**EAC**"), a Canadian-based corporation incorporated under the laws of the Province of British Columbia, and 1502987 B.C. Ltd. ("**DXI Subco**"), a wholly-owned subsidiary of the Company, pursuant to which the Company has agreed to acquire all of the issued and outstanding shares in the capital of VVT (the "**VVT Shares**") and EAC (the "**EAC Shares**"), as well as all other issued securities of VVT and EAC (the "**Proposed Transaction**"). Following the completion of the Proposed Transaction, the Company (the "**Resulting Issuer**") will continue the business of VVT, being a new medical treatment for varicose veins and will be listed on the TSXV under the life sciences sector.
- G. These unaudited condensed interim consolidated financial statements have been approved for filing by the board of directors on August 29, 2025.

VVT MED INC.
(formerly known as DXI Capital Corp.)
NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS
(Canadian dollars in thousands)

NOTE 2 – MATERIAL ACCOUNTING POLICIES

These condensed interim consolidated financial statements, including comparatives, have been prepared in accordance with International Accounting Standards ("IAS") 34, "Interim Financial Reporting" using accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). The financials were prepared based on the same accounting policy as the annual financial statements. These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company's annual financial statements for the years ending December 31, 2024 and 2023. Certain disclosures that are required to be included in annual financial statements prepared in accordance with IFRS are not included in these unaudited condensed interim consolidated financial statements. The accounting policies adopted in the preparation of these unaudited condensed interim consolidated financial statements are consistent with those followed in the preparation of the Company's audited financial statements for the years ended December 31, 2024 and 2023.

Functional, presentation and foreign currency

The Company's functional and presentation currency is the Canadian Dollar ("\$" or "CAD\$").

Going Concern

These unaudited condensed interim consolidated financial statements were prepared on a going concern basis. The going concern basis assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company incurred a net loss of \$113 during the six months ended June 30, 2025 and as of that date has a working capital deficiency of \$1,229 and an accumulated deficit of \$127,336.

The Company's ability to continue as a going concern is dependent upon attaining profitable operations and sourcing additional equity and debt capital from financiers, other than the present non-arm's length lenders to the Company, to provide the Company with sufficient capital to fund future operations or activities. There is no assurance that future operations or activities will be successful. These material uncertainties cast substantial doubt upon the Company's ability to continue as a going concern. These unaudited condensed interim consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities, the reported revenues and expenses, and the statement of financial position classifications used that would be necessary if the going concern assumptions were not appropriate.

Use of estimates and assumptions in the preparation of the financial statements

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. By their nature, these estimates are subject to measurement uncertainty and are reviewed periodically and adjustments, if necessary, are made in the year in which they are identified. Actual results could differ from those estimates.

VVT MED INC.
(formerly known as DXI Capital Corp.)
NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS
(Canadian dollars in thousands)

NOTE 3 – SIGNIFICANT EVENTS DURING THE REPORTING PERIOD

- 1) On March 24, 2025, the Company, VVT and EAC, received conditional acceptance from the TSXV for the Proposed Transaction. Final approval by the Exchange is subject to the Company satisfying various conditions including submission of final documentation, regulatory approvals, and completion of financing arrangements.
- 2) On May 21, 2025, the Company, VVT and EAC has filed a filing statement, dated effective May 15, 2025, with the Exchange in connection with its previously announced reverse take-over transaction (the "**RTO**") (the "**Filing Statement**"). The Filing Statement contains complete information regarding the RTO.

NOTE 4 – SHAREHOLDER LOANS FROM RELATED PARTIES

- 1) On February 8, 2022, the Company further entered into a loan agreement with both HEC and HVI, each for \$20. The loans bear interest at 8% per annum.
- 2) On May 4, 2022, the Company further entered into a loan agreement with both HEC and HVI, each for \$22.5. The loans bear interest at 8% per annum. In addition, the term of the total loans outstanding with HEC and HVI totaling \$600 were extended until December 31, 2022.
- 3) On October 18, 2022, the Company entered into another loan agreement with HEC and HVI for a total of \$27. The loans bear interest at 8% per annum.
- 4) On April 28, 2023, the Company entered into another loan agreement with HEC and HVI for a total of \$30. The loans bear interest at 8% per annum.
- 5) On August 3, 2023, the Company entered into another loan agreement with HEC and HVI for a total of \$30. The loans bear interest at 8% per annum.
- 6) On December 14, 2023, the Company entered into another loan agreement with HEC and HVI for a total of \$40. The loans bear interest at 8% per annum.
- 7) On April 8, 2024, the Company entered into another loan agreement with HEC and HVI for a total of \$40. The loans bear interest at 8% per annum.
- 8) On June 26, 2024, the Company entered into another loan agreement with HEC and HVI for a total of \$20. The loans bear interest at 8% per annum.
- 9) On October 17, 2024, the Company entered into another loan agreement with HEC and HVI for a total of \$20. The loans bear interest at 8% per annum.
- 10) On November 7, 2024, the Company entered into another loan agreement with HEC and HVI for a total of \$20. The loans bear interest at 8% per annum.
- 11) On March 10, 2025, the Company entered into another loan agreement with HEC and HVI for a total of \$30. The loans bear interest at 8% per annum.

VVT MED INC.
(formerly known as DXI Capital Corp.)
NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS
(Canadian dollars in thousands)

NOTE 4 – SHAREHOLDER LOANS FROM RELATED PARTIES (CONT.)

The aggregate sum of the principal loan amount is \$830 (December 31, 2024 - \$800) and accrued interest of \$232 (December 31, 2024 - \$203) at June 30, 2024 on the loans. The loans bear interest at 8% per year and are repayable on demand.

NOTE 5 – SHARE CAPITAL

The Company is authorized to issue an unlimited number of common voting shares, an unlimited number of first preferred shares issuable in series, and an unlimited number of second preferred shares issuable in series. No preferred shares have been issued and the terms of preferred shares have not been defined.

NOTE 6 – STOCK OPTIONS AND SHARE PURCHASE WARRANTS

a) Stock Options

The Stock Option Plan (the "**Plan**") is a 10% "rolling" plan pursuant to which the number of common shares reserved for issuance is 10% of the Company's issued and outstanding common shares as constituted on the date of any grant of options.

The Plan provides for the grant of options to purchase common shares to eligible directors, senior officers, employees and consultants of the Company ("**Participants**"). The exercise periods and vesting periods of options granted under the Plan are to be determined by the Company with approval from the Board of Directors. The expiration of any option will be accelerated if the participant's employment or other relationship with the Company terminates. The exercise price of an option is to be set by the Company at the time of grant but shall not be lower than the market price (as defined in the Plan) at the time of grant.

No stock options were issued or outstanding during the six months ended June 30, 2025 or 2024.

b) Share Purchase Warrants

No share purchase warrants were issued or outstanding during the periods ending June 30, 2025 or 2024.

NOTE 7 – RELATED PARTIES AND SHAREHOLDERS

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party's making of financial or operational decisions, or if both parties are controlled by the same third party. The Company has transactions with key management personnel, as summarized below. Transactions with related parties, if any, are incurred in the normal course of business and are measured at the exchange amount, which is the amount of consideration established and approved by the related parties. During the three and six months ended June 30, 2025 and 2024, in addition to the loans from related parties (note 4), the Company entered into the following transactions with related parties:

VVT MED INC.
(formerly known as DXI Capital Corp.)
NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS
(Canadian dollars in thousands)

NOTE 7 – RELATED PARTIES AND SHAREHOLDERS (CONT.)

- a) Compensation awarded to key management included a total of salaries and director and management fees for the six months ended June 30, 2025 was \$4 (2024 - \$3) and non-cash stock-based compensation of \$nil (2024 - \$nil). Key management includes the Company's officers and directors. The salaries and director fees are included in general and administrative expenses. Included in accounts payable and accrued liabilities at June 30, 2025 is \$100 (December 31, 2024 - \$105) owing to the officers and directors of the Company.
- b) Interest expenses of \$32 (2024 - \$16) were incurred during the six months ended June 30, 2025 related to loans from related parties.

NOTE 8 – SUBSEQUENT EVENTS

- 1) On July 16, 2025, DXI Capital Corp. had changed its name to "VVT MED INC." - the Resulting Issuer.
- 2) On July 22, 2025, VVT Med Inc. (formerly DXI Capital Corp.) has completed its previously announced acquisition of all of the outstanding securities of VVT and EAC pursuant to the terms of a definitive agreement dated September 30, 2024.

In connection with the completion of the Transaction, the Exchange conditionally approved the listing of the Company's common shares under the new ticker symbol "VVTM". The Transaction constituted a reverse takeover of the Company by VVT pursuant to Policy 5.2 of the TSXV.

The Transaction was completed according to the terms of a definitive agreement dated September 30, 2024 pursuant to which (i) the Company acquired all of the issued and outstanding securities of EAC by way of a three-cornered amalgamation with a wholly-owned subsidiary of the Company under the laws of the Province of British Columbia; and (ii) the Company acquired all of the issued and outstanding securities of VVT pursuant to a share exchange agreement entered into among the Company and each of VVT's securityholders.

As consideration, each VVT Share was exchanged for Company Shares on the basis of the exchange ratio for the VVT Shares set out in the Definitive Agreement. Each EAC Share was exchanged for one VVT Med Inc. Share. Any outstanding warrants or other exchangeable or convertible securities of EAC and VVT were exchanged, on an equivalent basis, for securities of VVT Med Inc.

Pursuant to the Transaction: (i) 2,053,571 VVT Med Inc. Shares were issued to creditors of the VVT Med Inc. in settlement of \$1,150,000 of debt, at a deemed price of CAD\$0.56 per VVT Med Inc. Share; (ii) 14,068,876 VVT Med Inc. Shares were issued in exchange for the outstanding EAC Shares (including 6,955,498 VVT Med Inc. Shares issued to holders of EAC subscription receipts); and (iii) 47,626,693 VVT Med Inc. Shares were issued to holders of the VVT Shares (including those issued upon conversion of the outstanding VVT convertible debentures).

VVT MED INC.
(formerly known as DXI Capital Corp.)
NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS
(Canadian dollars in thousands)

NOTE 8 – SUBSEQUENT EVENTS (CONT.)

Additionally, VVT Med Inc. has the following convertible securities issued and outstanding following the closing of the Transaction: (i) 1,553,651 stock options to purchase VVT Med Inc. Shares; (ii) 23,199,131 common share purchase warrants to purchase VVT Med Inc. Shares; and (iii) 299,915 broker warrants to purchase VVT Med Inc. Shares.

Following the Transaction, there are 66,311,431 VVT Med Inc. Shares issued and outstanding. For further details regarding the capitalization of the Company and VVT Med Inc., please see the Filing Statement.

- 3) On July 31, 2025, at market open, the Company Shares commenced trading on the TSX Venture Exchange under the symbol "VVTM".